Mirdametinib, a promising treatment for NF1-associated symptomatic plexiform neurofibroma, has shown remarkable long-term results. The ReNeu trial's findings, presented at a prestigious conference, revealed that with extended treatment, both adults and children experienced deeper and more sustained responses.
In adults, the confirmed objective response rate (ORR) increased to 47% over time, with a significant number of patients achieving a deep response. Similarly, in children, the ORR remained high at 55%, and the percentage of deep responses increased. These results are encouraging, as they indicate that mirdametinib can provide long-lasting tumor volume reductions.
The study also highlighted the importance of treatment duration. Dr. Angela Hirbe, the presenting author, emphasized that the longer patients stayed on mirdametinib, the more impressive the outcomes became. This included not only an increased number of responders but also a significant rise in patients with deep responses.
The ReNeu trial, a single-arm multicenter study, enrolled patients with symptomatic, inoperable NF1-associated PN causing significant morbidity. The trial design included a treatment phase with mirdametinib, followed by a long-term follow-up period. Patients received the drug as capsules or tablets, with a specific dosing schedule. The key endpoints focused on confirmed ORR, change in target PN volume, duration of response, and safety.
The long-term safety profile of mirdametinib in NF1-associated PN is reassuring. No new drug-related safety concerns emerged during the long-term follow-up. In adults, most treatment-related adverse effects were manageable, and serious TRAEs were rare. Similarly, in the pediatric population, TRAEs were generally mild to moderate, and dose adjustments were made when needed.
Previous data from the ReNeu trial, which led to FDA approval in 2025, showed impressive confirmed ORRs of 41% in adults and 52% in children. These results, along with improvements in pain and quality of life, supported the approval of mirdametinib for NF1 patients with symptomatic plexiform neurofibroma. The drug's conditional marketing authorization in Europe further emphasizes its potential.
In conclusion, mirdametinib has demonstrated its effectiveness and safety in treating NF1-associated symptomatic plexiform neurofibroma. The long-term data from the ReNeu trial provide valuable insights into the drug's benefits, especially with extended treatment. This breakthrough treatment offers hope and improved quality of life for patients with this challenging condition.
Stay informed and keep up with the latest oncology news and breakthroughs!
